Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 298

1.

Expression of subtype-specific group 1 leiomyosarcoma markers in a wide variety of sarcomas by gene expression analysis and immunohistochemistry.

Mills AM, Beck AH, Montgomery KD, Zhu SX, Espinosa I, Lee CH, Subramanian S, Fletcher CD, van de Rijn M, West RB.

Am J Surg Pathol. 2011 Apr;35(4):583-9. doi: 10.1097/PAS.0b013e318211abd6.

2.

Gene expression profiling in leiomyosarcomas and undifferentiated pleomorphic sarcomas: SRC as a new diagnostic marker.

Villacis RA, Silveira SM, Barros-Filho MC, Marchi FA, Domingues MA, Scapulatempo-Neto C, Aguiar S Jr, Lopes A, Cunha IW, Rogatto SR.

PLoS One. 2014 Jul 16;9(7):e102281. doi: 10.1371/journal.pone.0102281. eCollection 2014.

3.

Use of oxytocin receptor expression in distinguishing between uterine smooth muscle tumors and endometrial stromal sarcoma.

Loddenkemper C, Mechsner S, Foss HD, Dallenbach FE, Anagnostopoulos I, Ebert AD, Stein H.

Am J Surg Pathol. 2003 Nov;27(11):1458-62.

PMID:
14576480
4.

Expression profiling in soft tissue sarcomas with emphasis on synovial sarcoma, gastrointestinal stromal tumor, and leiomyosarcoma.

West RB.

Adv Anat Pathol. 2010 Sep;17(5):366-73. doi: 10.1097/PAP.0b013e3181ec7428. Review.

PMID:
20733355
5.

Genomic signatures predict poor outcome in undifferentiated pleomorphic sarcomas and leiomyosarcomas.

Silveira SM, Villacis RA, Marchi FA, Barros Filho Mde C, Drigo SA, Neto CS, Lopes A, da Cunha IW, Rogatto SR.

PLoS One. 2013 Jun 25;8(6):e67643. doi: 10.1371/journal.pone.0067643. Print 2013.

6.
7.

ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour.

Edris B, Espinosa I, M├╝hlenberg T, Mikels A, Lee CH, Steigen SE, Zhu S, Montgomery KD, Lazar AJ, Lev D, Fletcher JA, Beck AH, West RB, Nusse R, van de Rijn M.

J Pathol. 2012 Jun;227(2):223-33. doi: 10.1002/path.3986. Epub 2012 Feb 17.

8.

Use of myocardin in the classification of mesenchymal tumors of the uterus.

Liang J, Wu L, Xiao H, Li N, Wang H, Cheng C, Bai R, Zhao Y, Zheng H.

Int J Gynecol Pathol. 2010 Jan;29(1):55-62. doi: 10.1097/PGP.0b013e3181b1cdb0.

PMID:
19952936
9.

Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the duodenum: a clinicopathologic, immunohistochemical, and molecular genetic study of 167 cases.

Miettinen M, Kopczynski J, Makhlouf HR, Sarlomo-Rikala M, Gyorffy H, Burke A, Sobin LH, Lasota J.

Am J Surg Pathol. 2003 May;27(5):625-41.

PMID:
12717247
10.
11.

Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma.

Davidson B, Abeler VM, Hellesylt E, Holth A, Shih IeM, Skeie-Jensen T, Chen L, Yang Y, Wang TL.

Gynecol Oncol. 2013 Feb;128(2):349-55. doi: 10.1016/j.ygyno.2012.11.021. Epub 2012 Nov 21.

12.
13.

Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling.

Beck AH, Lee CH, Witten DM, Gleason BC, Edris B, Espinosa I, Zhu S, Li R, Montgomery KD, Marinelli RJ, Tibshirani R, Hastie T, Jablons DM, Rubin BP, Fletcher CD, West RB, van de Rijn M.

Oncogene. 2010 Feb 11;29(6):845-54. doi: 10.1038/onc.2009.381. Epub 2009 Nov 9.

14.

Differentiating soft tissue leiomyosarcoma and undifferentiated pleomorphic sarcoma: A miRNA analysis.

Guled M, Pazzaglia L, Borze I, Mosakhani N, Novello C, Benassi MS, Knuutila S.

Genes Chromosomes Cancer. 2014 Aug;53(8):693-702. doi: 10.1002/gcc.22179. Epub 2014 Apr 26.

PMID:
24771630
15.

miR-152 down-regulation is associated with MET up-regulation in leiomyosarcoma and undifferentiated pleomorphic sarcoma.

Pazzaglia L, Novello C, Conti A, Pollino S, Picci P, Benassi MS.

Cell Oncol (Dordr). 2017 Feb;40(1):77-88. doi: 10.1007/s13402-016-0306-4. Epub 2016 Nov 29.

PMID:
27900663
16.

Pleomorphic leiomyosarcoma: clinicopathologic and immunohistochemical study with special emphasis on its distinction from ordinary leiomyosarcoma and malignant fibrous histiocytoma.

Oda Y, Miyajima K, Kawaguchi K, Tamiya S, Oshiro Y, Hachitanda Y, Oya M, Iwamoto Y, Tsuneyoshi M.

Am J Surg Pathol. 2001 Aug;25(8):1030-8.

PMID:
11474287
17.

Differential gene expression in leiomyosarcoma.

Skubitz KM, Skubitz AP.

Cancer. 2003 Sep 1;98(5):1029-38.

18.

Use of histone deacetylase 8 (HDAC8), a new marker of smooth muscle differentiation, in the classification of mesenchymal tumors of the uterus.

de Leval L, Waltregny D, Boniver J, Young RH, Castronovo V, Oliva E.

Am J Surg Pathol. 2006 Mar;30(3):319-27.

PMID:
16538051
19.

Unsupervised analysis uncovers changes in histopathologic diagnosis in supervised genomic studies.

Nykter M, Hunt KK, Pollock RE, El-Naggar AK, Taylor E, Shmulevich I, Yli-Harja O, Zhang W.

Technol Cancer Res Treat. 2006 Apr;5(2):177-82.

PMID:
16551137
20.

Indistinguishable genomic profiles and shared prognostic markers in undifferentiated pleomorphic sarcoma and leiomyosarcoma: different sides of a single coin?

Carneiro A, Francis P, Bendahl PO, Fernebro J, Akerman M, Fletcher C, Rydholm A, Borg A, Nilbert M.

Lab Invest. 2009 Jun;89(6):668-75. doi: 10.1038/labinvest.2009.18. Epub 2009 Mar 16. Erratum in: Lab Invest. 2009 Jul;89(7):840.

Supplemental Content

Support Center